955373-72-5

Basic information

• Product Name: (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf
• Synonyms: (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf
• CAS NO: 955373-72-5
• Molecular Weight: 524.444
• Mol File: 955373-72-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf(955373-72-5)
• EPA Substance Registry System: (R)-4-benzyl-3-[(S)-2-(4-benzyloxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-onecf(955373-72-5)

Safety Data

• Hazardous Substances Data: 955373-72-5(Hazardous Substances Data)

Upstream product

• 886616-14-4 5-benzyloxy-2-bromomethyl-1,3-dichloro-benzene 
• 155399-10-3 (4R)-3-(4-pentenoyl)-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 39716-58-0 pent-4-enoyl chloride 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 94278-70-3 2-(bromomethyl)-1,3-dichloro-5-methoxybenzene 

Downstream Products

• 955373-73-6 (R)-4-((R)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-benzyloxy-2,6-dichloro-benzyl)-4-oxo-butyraldehyde 
• 955406-47-0 (3R)-3-(2,6-Dichloro-4-hydroxy-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-7-yl)-pyrrolidin-2-one 
• 955406-39-0 (R)-3-(2,6-dichloro-4-hydroxy-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-4-yl)-pyrrolidin-2-one 
• 955406-53-8 (3R)-3-(2,6-Dichloro-4-hydroxy-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-6-yl)-pyrrolidin-2-one 
• 955406-46-9 (3R)-3-(4-Benzyloxy-2,6-dichloro-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-7-yl)-pyrrolidin-2-one 
• 955407-68-8 (3R)-3-(3,5-Dichloro-4'-fluoro-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-indazol-7-yl)-pyrrolidin-2-one 
• 955407-70-2 (3R)-3-(3,5-Dichloro-4'-fluoro-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-indazol-6-yl)-pyrrolidin-2-one 
• 955407-66-6 (3R)-3-(3,5-dichloro-4'-fluoro-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-indazol-4-yl)-pyrrolidin-2-one 
• 955406-52-7 (3R)-3-(4-benzyloxy-2,6-dichloro-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-6-yl)-pyrrolidin-2-one 
• 955406-38-9 (R)-3-(4-benzyloxy-2,6-dichloro-benzyl)-1-(4,5,6,7-tetrahydro-1H-indazol-4-yl)-pyrrolidin-2-one 
• 955407-77-9 (3R)-3-(3,5-Dichloro-4'-trifluoromethyl-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-indazol-4-yl)-pyrrolidin-2-one 
• 955406-21-0 (3R,5R)-3-(2,6-dichloro-4-hydroxy-benzyl)-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-2-one 
• 955406-15-2 (3R,5S)-3-(4-hydroxy-2,6-dichloro-benzyl)-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-2-one 
• 955407-49-5 (3R,5R)-(+)-3-(3,5-dichloro-4'-fluoro-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-2-one 

Relevant articles and documents

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity.